AstraZeneca is leaving no stone unturned in its effort to make baxdrostat the first aldosterone synthase inhibitor (ASI) to get approval for hard-to-treat hypertension. The FDA has now started a ...
Refreshment is your ultimate resource for staying informed and up-to-date on the water cooler, vending, and office coffee sectors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results